Coherus (CHRS) Q2 Revenue Jumps 10%

Coherus Oncology (CHRS) reported Q2 2025 GAAP revenue of $10.3 million, surpassing estimates by 10.2% on robust LOQTORZI sales of $10.0 million, a 163% year-over-year increase. However, non-GAAP EPS missed expectations at $(0.34) due to elevated R&D and SG&A expenses. The recent UDENYCA divestiture significantly bolstered cash and marketable securities to $237.6 million, extending the cash runway through late 2026 to support its focused immuno-oncology pipeline. While top-line growth and financial flexibility are strong, the company faces ongoing profitability challenges and significant reliance on LOQTORZI, with key pipeline data not expected until H1 2026.

Analysis

Coherus Oncology's Q2 2025 results present a company in a critical strategic transition, marked by a significant top-line beat but underlying profitability challenges. GAAP revenue of $10.3 million surpassed analyst estimates by 10.2%, driven almost entirely by the impressive performance of its PD-1 inhibitor, LOQTORZI, which generated $10.0 million in net sales, a 163% year-over-year increase. This growth reflects successful market penetration in its approved indication for nasopharyngeal carcinoma (NPC), supported by its preferred status in NCCN guidelines. However, this commercial success is contrasted by a wider-than-expected non-GAAP loss per share of $(0.34), missing the consensus of $(0.22), as elevated R&D and SG&A expenses continue to weigh on the bottom line. The company's financial profile has been fundamentally reshaped by the divestiture of its UDENYCA franchise, which fortified the balance sheet with $237.6 million in cash and marketable securities. This move extends the operational runway through late 2026, providing crucial funding for its focused immuno-oncology pipeline. While this de-risks the medium term, the company's investment thesis now hinges on two factors: continued expansion of LOQTORZI in a niche market and the successful clinical development of its pipeline assets, CHS-114 and casdozokitug, for which pivotal data is not expected until the first half of 2026.

Key Decisions for Investors

• Investors should closely monitor LOQTORZI's quarterly sales growth and market penetration, particularly among community oncologists, as it remains the sole revenue driver and a key barometer of near-term execution.
• Given the extended cash runway to late 2026, the primary focus shifts to pipeline catalysts; however, with key clinical data for CHS-114 and casdozokitug not expected until H1 2026, the stock is best suited for long-term investors with a high tolerance for clinical development risk.
• It is prudent to track quarterly cash burn relative to the company's financial guidance and be mindful of the $96.8 million in UDENYCA-related accrued liabilities, which represents a significant near-term call on cash.
• Consider the current valuation in the context of a pure-play immuno-oncology company with a fortified balance sheet but significant dependency on a single niche product until its pipeline matures.